Did you miss any important news last month? Check out our top 5 most popular articles from December.
A previous study reported tranexamic acid’s ability to dose dependently induce emesis in dogs. To date, though, a safety and efficacy profile for veterinary use of tranexamic acid has not been determined. To address this knowledge gap, a Japanese research team investigated the safety and efficacy of IV tranexamic acid for inducing emesis in dogs.
4. Earlier Play Leads to More Confident Puppies
The prime time for puppy socialization is generally thought to be from 3 to 14 weeks of age, but a new study has shown that beginning the socialization process even earlier may bring important benefits for the behavioral welfare of puppies as they age.
3. AVMA 2017: Managing Oral Tumors in Dogs
Early detection and prompt treatment can lead to good outcomes for dogs with oral tumors, but veterinarians need to know how to spot these lesions, according to Erin D. Vicari, VMD, DAVDC, of the Animal Emergency and Referral Center of Minnesota in Oakdale. In a lecture at the 2017 American Veterinary Medical Association Convention in Indianapolis, Indiana.
2. How to Keep Your Christmas Tree Pet-Free
This year, you didn’t have to choose between your pets and your tree. Instead, you followed these simple tips to keep your tree pet-free—and upright—all season long.
1. Clinical Trial Shows Promise for FIP Treatment
Researchers have spent years searching for a cure for feline infectious peritonitis (FIP)—an uncommon, but usually fatal, immune response to feline coronavirus (FCoV). And now, a new clinical trial is believed to have made a treatment breakthrough. Researchers from Kansas State University and the University of California, Davis, came together to investigate whether a novel antiviral drug could cure cats with FIP.
Podcast CE: Using Novel Targeted Treatment for Canine Allergic and Atopic Dermatitis
December 20th 2024Andrew Rosenberg, DVM, and Adam Christman, DVM, MBA, talk about shortcomings of treatments approved for canine allergic and atopic dermatitis and react to the availability of a novel JAK inhibitor.
Listen